AskBio Shares Interim Safety Data for AB-1003 in LGMD 2I/R9 Trial
AskBio Reports Interim Safety Data from Phase 1/2 LION-CS101 Trial of AB-1003 in Limb-Girdle Muscular Dystrophy 2I/R9 AskBio Inc. (AskBio), a gene therapy company wholly owned by Bayer AG and…
Zoetis Gets CVMP Green Light for Lenivia® to Relieve Canine Osteoarthritis Pain
Zoetis Receives Positive CVMP Opinion for Lenivia®, a Novel Therapy to Reduce Osteoarthritis Pain in Dogs Zoetis Inc., a global leader in animal health, today announced that the Committee for…
Satellos Reports Positive Safety and Functional Data for SAT-3247 in DMD First-in-Human Study
Satellos Bioscience Reports Promising Safety, Tolerability, and Functional Benefits of SAT-3247 in Adults with Duchenne Muscular Dystrophy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on…
Pulse Biosciences Presents Late-Breaking nPulse™ Cardiac System Data at EACTS 2025
Pulse Biosciences Unveils Promising First-in-Human Feasibility Data for the nPulse™ Cardiac Surgical System at EACTS 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical-stage medical technology company pioneering the use of…
Prilenia and Ferrer to Present New Pridopidine Data in Huntington’s Disease at HSG Congress
Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of…
Bristol Myers Squibb Acquires Orbital Therapeutics to Expand Cell Therapy Portfolio
Bristol Myers Squibb Expands and Diversifies RNA and Cell Therapy Portfolio Through Acquisition of Orbital Therapeutics Bristol Myers Squibb (NYSE: BMY) announced a significant strategic move to strengthen its leadership…
Johnson & Johnson Urges Shareholders to Reject Tutanota Mini-Tender Offer
Johnson & Johnson Urges Shareholders to Reject Below-Market “Mini-Tender” Offer by Tutanota LLC Johnson & Johnson (NYSE: JNJ) has issued a formal statement warning its shareholders against an unsolicited “mini-tender”…
Novo Nordisk to Acquire Akero Therapeutics to Strengthen MASH Pipeline
Novo Nordisk to Acquire Akero Therapeutics to Strengthen MASH Pipeline with Phase 3 FGF21 Analogue Efruxifermin Novo Nordisk, a global healthcare leader in diabetes and obesity treatments, has announced a…
Vividion Publishes Preclinical Data in Science on Novel RAS-PI3K Inhibitors Blocking Tumor Growth
Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG,…
Perceptive Imaging Appoints Doug Fulling as CEO to Lead Growth and Innovation
Perceptive Imaging Appoints Doug Fulling as CEO to Lead Global Growth, Enhance Services, and Drive Innovation in Clinical Trial Imaging Perceptive Imaging (“Perceptive” or “the Company”), a global leader in…
Eikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD
Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative…
Genethon Reports 2-Year Efficacy of Low-Dose Gene Therapy GNT0004 in Duchenne Muscular Dystrophy
Genethon Presents 2-Year Efficacy Results of Low-Dose Micro-Dystrophin Gene Therapy (GNT0004) in Duchenne Muscular Dystrophy at ESGCT 2025 Genethon, a global leader in the research and development of gene therapies…